NasdaqCM:ESTAMedical Equipment
Will Record Motiva Sales and Surging Margins Redefine Establishment Labs' (ESTA) Core Growth Narrative?
In early 2026, Establishment Labs Holdings announced that it had sold more than 5 million Motiva breast implant devices globally and reported fourth-quarter 2025 results with revenue growth above 25% for 2025, a 45% year-over-year revenue increase in Q4, and an expanded gross margin driven in part by its U.S. launch and minimally invasive platform.
This combination of a major product milestone and stronger-than-expected financial performance suggests that Motiva’s U.S. adoption and...